{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:28:36Z","timestamp":1781270916735,"version":"3.54.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.berh.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T21:40:39Z","timestamp":1539207639000},"page":"401-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Disease activity assessment in patients with psoriatic arthritis"],"prefix":"10.1016","volume":"32","author":[{"given":"Andreas","family":"Kerschbaumer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2018.08.004_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.08.004_bib2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.08.004_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2018.08.004_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.08.004_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2018.08.004_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","article-title":"Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype","volume":"17","author":"Fitzgerald","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2018.08.004_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/ard.2011.155044","article-title":"Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis","volume":"71","author":"Eder","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2018.08.004_bib8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2018.08.004_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.08.004_bib10","unstructured":"Janssen Research & Development L. A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFa Naive Participants With Active Radiographic Axial Spondyloarthritis. https:\/\/clinicaltrials gov\/ct2\/show\/results\/NCT02437162?sect=X70156#outcome1 2018;(accessed 15 July 2018)."},{"key":"10.1016\/j.berh.2018.08.004_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.08.004_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2018.08.004_bib13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2018.08.004_bib14","first-page":"627","article-title":"Psoriatic arthritis","volume":"21","author":"Wright","year":"1971","journal-title":"Bull Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2018.08.004_bib15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3899\/jrheum.160904","article-title":"Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016","volume":"44","author":"Orbai","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.08.004_bib16","series-title":"Assessing disease activity in rheumatoid arthritis - the EULAR handbook of standard methods. On behalf of the EULAR standing committee for international clinical studies including therapeutic trials - ESCISIT (chairman: smolen JS)","author":"Scott","year":"1993"},{"issue":"12","key":"10.1016\/j.berh.2018.08.004_bib17","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/ard.2010.131201","article-title":"Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab","volume":"69","author":"Klarenbeek","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.08.004_bib18","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1136\/ard.2011.153734","article-title":"Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression","volume":"70","author":"Aletaha","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.08.004_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/art.1780080214","article-title":"A\u00a0seven day variability study of 499 patients with peripheral rheumatoid arthritis","volume":"8","year":"1965","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2018.08.004_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/art.11417","article-title":"Assessment of patients with psoriatic arthritis: a review of currently available measures","volume":"50","author":"Gladman","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"147","key":"10.1016\/j.berh.2018.08.004_bib21","first-page":"393","article-title":"Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis","volume":"37","author":"Ritchie","year":"1968","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.berh.2018.08.004_bib22","first-page":"716","article-title":"Grading of tenderness as a source of interrater error in the Ritchie articular index","volume":"12","author":"Hart","year":"1985","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.08.004_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.1780380106","article-title":"Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity","volume":"38","author":"Smolen","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.08.004_bib24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/art.1780370406","article-title":"Reduced joint counts in controlled clinical trials in rheumatoid arthritis","volume":"37","author":"Fuchs","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2018.08.004_bib25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2018.08.004_bib26","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2018.08.004_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.08.004_bib28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/ard.2007.084244","article-title":"Development and validation of the spondyloarthritis research Consortium of Canada (SPARCC) enthesitis index","volume":"68","author":"Maksymowych","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2018.08.004_bib29","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/art.1780390912","article-title":"Dactylitis in patients with seronegative spondylarthropathy. Assessment by ultrasonography and magnetic resonance imaging","volume":"39","author":"Olivieri","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2018.08.004_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2014-205839","article-title":"High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis","volume":"74","author":"Tan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2018.08.004_bib31","first-page":"1745","article-title":"Development of an assessment tool for dactylitis in patients with psoriatic arthritis","volume":"32","author":"Helliwell","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2018.08.004_bib32","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.08.004_bib33","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.08.004_bib34","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.berh.2018.08.004_bib35","first-page":"2286","article-title":"A\u00a0new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2018.08.004_bib36","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.08.004_bib37","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1136\/ard.2010.129726","article-title":"Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?","volume":"69","author":"Eder","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2018.08.004_bib38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis--oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"2","key":"10.1016\/j.berh.2018.08.004_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","article-title":"Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality","volume":"141","author":"Ashcroft","year":"1999","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2018.08.004_bib40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.berh.2018.08.004_bib41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","article-title":"Nail psoriasis: a review of treatment options","volume":"76","author":"Pasch","year":"2016","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.berh.2018.08.004_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2018.08.004_bib43","first-page":"123","article-title":"The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"6 Suppl 43","key":"10.1016\/j.berh.2018.08.004_bib44","first-page":"S045","article-title":"Remission of rheumatoid arthritis: should we care about definitions?","volume":"24","author":"Aletaha","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.08.004_bib45","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis. The committee on outcome measures in rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.08.004_bib46","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.100857","article-title":"Patient global assessment in psoriatic arthritis: a\u00a0multicenter GRAPPA and OMERACT study","volume":"38","author":"Cauli","year":"2011","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2018.08.004_bib47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2018.08.004_bib48","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1353\/pbm.1993.0004","article-title":"Regulation of the acute phase response by cytokines","volume":"36","author":"Kushner","year":"1993","journal-title":"Perspect Biol Med"},{"issue":"8","key":"10.1016\/j.berh.2018.08.004_bib49","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","article-title":"Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients","volume":"31","author":"Van der Heijde","year":"1992","journal-title":"Br J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2018.08.004_bib50","first-page":"425","article-title":"Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants","volume":"21","author":"van Leeuwen","year":"1994","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.08.004_bib51","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2018.08.004_bib52","first-page":"333","article-title":"A\u00a0theoretical framework for process, outcome and prognosis in rheumatoid arthritis","volume":"19","author":"Kirwan","year":"1992","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.08.004_bib53","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/art.22052","article-title":"Measuring function in rheumatoid arthritis: identifying reversible and irreversible components","volume":"54","author":"Aletaha","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.08.004_bib54","article-title":"The effects of structural damage on functional disability in psoriatic arthritis","author":"Kerschbaumer","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.08.004_bib55","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.22443","article-title":"A\u00a0longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time?","volume":"56","author":"Husted","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 11","key":"10.1016\/j.berh.2018.08.004_bib56","first-page":"S64","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl. 2","key":"10.1016\/j.berh.2018.08.004_bib57","doi-asserted-by":"crossref","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","article-title":"Psoriatic arthritis imaging: a review of scoring methods","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.08.004_bib58","series-title":"Encyclopedia of behavioral medicine","article-title":"Psychometric properties","author":"Ginty","year":"2013"},{"key":"10.1016\/j.berh.2018.08.004_bib59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.08.004_bib60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A\u00a0simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.berh.2018.08.004_bib61","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.08.004_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.51.2.177","article-title":"Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis","volume":"51","author":"van der Heijde","year":"1992","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.08.004_bib63","first-page":"575","article-title":"Interpretation and power of a pooled index","volume":"20","author":"Goldsmith","year":"1993","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.08.004_bib64","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2018.08.004_bib65","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/ard.2009.117945","article-title":"Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis","volume":"69","author":"Nell-Duxneuner","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.08.004_bib66","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","article-title":"Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression","volume":"76","author":"Aletaha","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.08.004_bib67","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1136\/annrheumdis-2015-208521","article-title":"Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates","volume":"74","author":"Schoels","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.08.004_bib68","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2018.08.004_bib69","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.08.004_bib70","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3899\/jrheum.140172","article-title":"Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response","volume":"41","author":"Helliwell","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.08.004_bib71","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","author":"Helliwell","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2018.08.004_bib72","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken )"},{"issue":"2","key":"10.1016\/j.berh.2018.08.004_bib73","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.2010.129379","article-title":"Development of a preliminary composite disease activity index in psoriatic arthritis","volume":"70","author":"Mumtaz","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.08.004_bib74","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2018.08.004_bib75","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.22204","article-title":"Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab","volume":"66","author":"Helliwell","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.berh.2018.08.004_bib76","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard.2006.056457","article-title":"Predictors for radiological damage in psoriatic arthritis: results from a single centre","volume":"66","author":"Bond","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2018.08.004_bib77","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.23345","article-title":"Radiographic progression in psoriatic arthritis achieving a good response to treatment: data using newer composite indices of disease activity","volume":"70","author":"Helliwell","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.berh.2018.08.004_bib78","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.berh.2018.08.004_bib79","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/annrheumdis-2011-200093","article-title":"Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set","volume":"71","author":"Fitzgerald","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.08.004_bib80","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1099-1379(199809)19:5<453::AID-JOB2899>3.0.CO;2-9","article-title":"Aggregation or aggravation? The relative merits of a broad withdrawal construct","volume":"19","author":"Johns","year":"1998","journal-title":"J\u00a0Organiz Behav"},{"key":"10.1016\/j.berh.2018.08.004_bib81","series-title":"The Dependability of Measurements: theory of Generalizability for Scores and Pro\u00aeles","year":"1972"},{"issue":"Suppl. 2","key":"10.1016\/j.berh.2018.08.004_bib82","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/annrheumdis-2017-eular.3762","article-title":"Outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.08.004_bib83","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1136\/annrheumdis-2015-208509","article-title":"The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?","volume":"74","author":"Helliwell","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169421830041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169421830041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:19:24Z","timestamp":1761499164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169421830041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S152169421830041X"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2018.08.004","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease activity assessment in patients with psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}